Xtant Medical (NYSEAMERICAN:XTNT) Share Price Passes Above 200 Day Moving Average - Here's Why

Key Points

• Xtant Medical's stock price recently exceeded its 200-day moving average of $0.59, reaching a high of $0.65 during trading.
• The company has seen significant institutional investment, with major firms like Nantahala Capital Management LLC increasing their holdings by over 500% in the past quarter.
• Xtant Medical specializes in regenerative medicine products for orthopedic and neurological use, offering a range of innovative medical devices.

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - )'s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.59 and traded as high as $0.65. Xtant Medical shares last traded at $0.65, with a volume of 80,915 shares trading hands.

Xtant Medical Stock Down 0.4%

The business has a 50-day simple moving average of $0.63 and a two-hundred day simple moving average of $0.59. The stock has a market capitalization of $90.50 million, a P/E ratio of -16.16 and a beta of -0.22. The company has a quick ratio of 1.16, a current ratio of 2.47 and a debt-to-equity ratio of 0.46.

Institutional Trading of Xtant Medical

Large investors have recently bought and sold shares of the stock. Jane Street Group LLC bought a new stake in Xtant Medical in the second quarter valued at $26,000. Mink Brook Asset Management LLC grew its holdings in shares of Xtant Medical by 125.8% during the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company's stock worth $81,000 after purchasing an additional 60,997 shares during the last quarter. Crescent Grove Advisors LLC grew its holdings in shares of Xtant Medical by 94.3% during the second quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company's stock worth $304,000 after purchasing an additional 200,000 shares during the last quarter. AWM Investment Company Inc. bought a new stake in shares of Xtant Medical during the second quarter worth $4,875,000. Finally, Nantahala Capital Management LLC grew its holdings in shares of Xtant Medical by 500.3% during the second quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company's stock worth $50,543,000 after purchasing an additional 57,000,000 shares during the last quarter. 69.33% of the stock is currently owned by institutional investors.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.